stockrow
Saturday 7 November 2026
Export PHAT’s income statement to Excel — free account
Phathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024.
- Revenue
- +71.1%
- EPS
- +60.1%
- Free cash flow
- +112.2%
- Total debt
- −20.1%
Quarter to September 2026, against a year earlier
5.23
0.15
+2.95%
Follow PHAT
Alert me
Phathom Pharmaceuticals, Inc. (PHAT) P/E ratio
Phathom Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| ARVN Arvinas, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 2.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)